GlassScriptPhysician profile
James M Orsini
NPI 1659516813
$24,330.88
in general payments reported to CMS, 2019-2025
58 companies · $726 in 2025
The $726 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,482 · 2021: $1,938 · 2022: $3,881 · 2023: $1,256 · 2024: $694 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.71 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $6,618.63 | 2019-2023 | Adcetris |
| Janssen Biotech, INC. | $3,963.04 | 2019-2024 | Darzalex |
| Exelixis INC. | $3,336.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $2,408.09 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Astellas Pharma US INC | $1,960.56 | 2019-2023 | Padcev |
| Novartis Pharmaceuticals Corporation | $1,337.52 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $812.13 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $517.64 | 2019-2025 | Opdivo, Eliquis |
| Merck Sharp & Dohme LLC | $382.66 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $370.11 | 2019-2025 | Jakafi |
| Amgen INC. | $205.15 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $201.14 | 2019-2023 | Imbruvica, Epkinly |
| Karyopharm Therapeutics INC. | $188.47 | 2020-2025 | Xpovio |
| Eisai INC. | $130.95 | 2019-2022 | |
| Galvanize Therapeutics, INC | $119.74 | 2023 | Aliya System |
Show all 55 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Orsini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.